Skip to content
Image of Webinar Series Title

Industry Partner Update: PepGen

Starts April 10, 2024
10:00 AM
11:00 AM
Event Type: Virtual
Event Category: Research
Audience Type: Everyone

Defeat Duchenne Canada is committed to bringing the latest in Duchenne muscular dystrophy research and drug development to you – our Canadian Duchenne community.

Join the latest webinar from PepGen, as they discuss the latest information about PGN-EDO51, the company’s lead product candidate for the treatment of people living with Duchenne muscular dystrophy whose mutations are amenable to exon 51 skipping, as well as details on their upcoming studies, including CONNECT1 in Canada.

Complete the Registration Form below to receive the Zoom link
Have questions for PepGen? Click the button to your left.

 

CONNECT1-ED051 Participants Needed: PepGen is actively recruiting participants for their study to evaluate the safety and tolerability of multiple ascending intravenous (IV) doses of PGN-EDO51 administered to participants with Duchenne muscular dystrophy. Participants must be male by birth, at least 8 years old, and diagnosed with Duchenne amenable to exon 51 skipping. Locations in New Brunswick, Ontario, and Quebec.

Learn more about PGN-EDO51 and earlier-stage candidates for other exons during this webinar.

Click the button to the left to learn more about the study, or contact them by email at [email protected].

 

About PGN-EDO51: PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology is engineered to optimize the delivery of therapeutic oligonucleotides, including exon-skipping oligonucleotides, which is a major challenge that limits their efficacy. PGN-EDO51 is being evaluated for the treatment of Duchenne muscular dystrophy (DMD), which is amenable to exon 51 skipping. In 2023, PepGen is planning to initiate two clinical trials to assess the safety and efficacy of repeat doses of PGN-EDO51 in boys and young men living with DMD.

Click the button to the left to read their latest press release.